Related Experiment Video
Updated: Jun 17, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding
1Department of Medicine, McMaster University and Henderson Research Center, Hamilton, ON, Canada. schulms@mcmaster.ca
Insights
Antithrombotic therapy for coronary artery disease offers net benefit, especially in severe cases. However, prolonged combination treatments require de-escalation as patient stability increases to balance efficacy and safety.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Antithrombotic treatment for coronary artery disease (CAD) is increasingly complex, involving combinations of antiplatelet agents and anticoagulants.
- Traditional treatments like unfractionated heparin and warfarin are being replaced by newer agents such as low-molecular-weight heparin, fondaparinux, and direct thrombin inhibitors.
- Major bleeding complications raise questions about the overall benefit of these intensive antithrombotic strategies.
Purpose of the Study:
- To review and discuss the net benefit of antithrombotic therapy in coronary artery disease.
- To compare the efficacy and safety profiles of various antithrombotic agents and combinations.
- To provide guidance on de-escalating antithrombotic treatment based on patient stabilization and risk-benefit assessment.
Main Methods:
- Review of current literature on antithrombotic therapies in coronary artery disease.
- Numerical comparison of absolute risk reductions versus increases in bleeding risks.
- Qualitative assessment of individual antithrombotic components in achieving net benefit.
Main Results:
- Antithrombotic therapy demonstrates a net benefit in most patients with coronary artery disease, except for primary prophylaxis in low-to-moderate risk individuals.
- The net benefit generally increases with the severity of the coronary condition, even with multiple combined antithrombotic drugs.
- Prolonged combination therapy may not be beneficial as the patient stabilizes, necessitating treatment de-escalation.
Conclusions:
- Antithrombotic therapy is crucial for managing coronary artery disease, offering significant benefits that often outweigh risks.
- Treatment strategies must be individualized, balancing efficacy with safety, and adapted over time.
- De-escalation of antithrombotic therapy is essential once the acute phase of the coronary condition has passed to minimize bleeding risks.
Abstract:
The antithrombotic treatment of coronary artery disease is becoming increasingly complex. Aspirin is often combined with more potent antiplatelet agents such as thienopyridines and glycoprotein IIb/IIIa inhibitors. The classic anticoagulant unfractionated heparin is giving way to low-molecular-weight heparin, the pentasaccharide fondaparinux and the direct thrombin inhibitor bivalirudin. Warfarin (or another vitamin K antagonist) and antiplatelet agents are often required in combination for several months. Patients and physicians who have experienced major bleeding complications sometimes question the benefit of these treatment strategies. It is therefore crucial to try and weigh the impact on efficacy against safety. In this review the net benefit is discussed both numerically, comparing absolute reductions vs. increases in risks, and also by addressing the qualitative importance of each component in reaching the net benefit. Except for primary prophylaxis in patients at low-moderate risk for coronary events, there is a net benefit of antithrombotic therapy. With increasing severity of the coronary condition the net benefit generally prevails even with an increasing number of antithrombotic drugs combined. However, as the patient slowly stabilizes after appropriate interventions, it is necessary to de-escalate the treatment in accordance with decreasing net benefit of prolonged combination therapy.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:27Coronary Artery Disease V: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...